# Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

> **NCT05970705** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 101 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Trifluridine/Tipiracil

## Key facts

- **NCT ID:** NCT05970705
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-07-04
- **Final completion:** 2026-07-04
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970705, "Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05970705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*